CheckMate -743, a phase III trial evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in previously untreated malignant pleural mesothelioma met its primary endpoint of overall survival.
The phase III CheckMate-9ER trial evaluating Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma met its primary endpoint of progression-free survival at final analysis.
In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute report.
A team of investigators from Winship Cancer Institute of Emory University has shown outstanding long term survival results for multiple myeloma patients from a 3-drug induction regimen in a study published in the Journal of Clinical Oncology.
Cue Biopharma Inc. and Merck are evaluating the combination of Cue Biopharma's investigational product candidate CUE-101, a first-in-class biologic, with Merck's Keytruda in patients with advanced head and neck cancer.
Researchers, patient advocates, and global oncology leaders who have worked to transform cancer care around the world are among the recipients of the American Society of Clinical Oncology's Special Awards—the society's highest honors—and Conquer Cancer, the ASCO Foundation Women Who Conquer Cancer Mentorship Awards.
Jonathan Serody was named chief of hematology and Ethan Basch was named chief of oncology at University of North Carolina School of Medicine Department of Medicine.
Jenny Poynter and Daniel Harki were appointed to the leadership team of Masonic Cancer Center April 15.
The American Heart Association has awarded $17 million in scientific research to be led by scientists from Boston University, the Ohio State University and Yale University to study the health impacts of e-cigarettes and other nicotine delivery systems on youth and young adults.
